Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(117 products)
- EGFR(581 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2379 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
AMG-Tie2-1
CAS:AMG-Tie2-1 is a Tie2 and VEGFR2 inhibitor with anticancer and antitumor activity for the study of cardiovascular disease and cancer.Formula:C25H20F3N5O2Purity:98.9%Color and Shape:SolidMolecular weight:479.45EGFR-IN-56
CAS:EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.Formula:C23H22N4O3SColor and Shape:SolidMolecular weight:434.51Infigratinib phosphate
CAS:Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, andFormula:C26H34Cl2N7O7PPurity:99.24% - 99.6%Color and Shape:SolidMolecular weight:658.47PD180970
CAS:PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.Formula:C21H15Cl2FN4OPurity:98.67%Color and Shape:SolidMolecular weight:429.27TM-233
CAS:TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.Formula:C25H20O4Purity:98%Color and Shape:SolidMolecular weight:384.42BLK-IN-2
CAS:BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。Formula:C39H41N9O3Color and Shape:SolidMolecular weight:683.8BCR-ABL-IN-2
CAS:BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).Formula:C24H25Cl2N5O3Purity:98%Color and Shape:SolidMolecular weight:502.39JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formula:C23H22FN5O4SPurity:99.75%Color and Shape:SolidMolecular weight:483.52Depatuxizumab mafodotin
CAS:Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].Color and Shape:LiquidMAX-40279 hemifumarate
CAS:MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.Formula:C48H50F2N12O6S2Color and Shape:SolidMolecular weight:993.12TG 100801 Hydrochloride
CAS:TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.Formula:C33H31Cl2N5O3Purity:98%Color and Shape:SolidMolecular weight:616.54Atopaxar Hydrobromide
CAS:Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.Formula:C29H39BrFN3O5Purity:98%Color and Shape:SolidMolecular weight:608.54EGFR-IN-64
CAS:EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.Formula:C20H21N3O3Color and Shape:SolidMolecular weight:351.4DB07107
CAS:DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).Formula:C23H22N4OPurity:98%Color and Shape:SolidMolecular weight:370.45AC430
CAS:AC430, a specific JAK2 inhibitor for cancer and autoimmune therapy, excels in preclinical trials with low doses. Developed by Ambit.Formula:C19H16FN5OColor and Shape:SolidMolecular weight:349.36Aminoquinuride
CAS:Surfen, or Aminoquinuride, reduces inflammation but blocks remyelination in MS mouse models and regulates murine T cell activation.Formula:C21H20N6OColor and Shape:SolidMolecular weight:372.42HKI-357 dimaleate
CAS:HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.Formula:C39H37ClFN5O11Color and Shape:SolidMolecular weight:806.2KL-1156
CAS:KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.Formula:C17H17NO4Purity:98%Color and Shape:SolidMolecular weight:299.32Rogaratinib
CAS:Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR).Formula:C23H26N6O3SPurity:99.54%Color and Shape:SolidMolecular weight:466.56Spebrutinib besylate
CAS:Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).Formula:C28H28FN5O6SPurity:98%Color and Shape:SolidMolecular weight:581.62FGFR2-IN-2
CAS:FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.Formula:C23H22N4OPurity:98.09%Color and Shape:SolidMolecular weight:370.45Sch 13835
CAS:Sch 13835 is an inhibitor of platelet derived growth factor.Formula:C15H10ClNO4SPurity:98%Color and Shape:SolidMolecular weight:335.76EGFR T790M/L858R-IN-5
CAS:EGFR T790M/L858R-IN-5 (example 52) functions as a potent EGFR T790M/L858R inhibitor, demonstrating a 92.9% inhibition rate at a concentration of 0.05 μM [1].Formula:C28H31N9OMolecular weight:509.61EL-102
CAS:EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.Formula:C19H16N2O3S2Purity:99.34%Color and Shape:SolidMolecular weight:384.47Ref: TM-T15205
1mg93.00€5mg205.00€10mg331.00€25mg515.00€50mg700.00€100mg1,044.00€1mL*10mM (DMSO)173.00€FN-1501
CAS:FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).Formula:C22H25N9OPurity:97.4%Color and Shape:SolidMolecular weight:431.49Ref: TM-T15335
1mg87.00€5mg177.00€10mg295.00€25mg537.00€50mg807.00€100mg1,099.00€1mL*10mM (DMSO)203.00€HS-438
CAS:HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Formula:C17H17N3O3SColor and Shape:SolidMolecular weight:343.4Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Formula:C19H18BrClN6OPurity:97.03%Color and Shape:SolidMolecular weight:461.74FLT3/ITD-IN-2
CAS:FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.Formula:C23H26F3N7O2Color and Shape:SolidMolecular weight:489.49TK4b
CAS:TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).Formula:C21H22N2O2Color and Shape:SolidMolecular weight:334.41Nuvenzepine
CAS:Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.Formula:C19H20N4O2Purity:98%Color and Shape:SolidMolecular weight:336.39TX-1918
CAS:TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.Formula:C14H12O3Color and Shape:SolidMolecular weight:228.24pan-HER-IN-1
CAS:Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.Formula:C19H14BrN5OColor and Shape:SolidMolecular weight:408.25AAE871
CAS:AAE871 is a type I FLT3 inhibitor.Formula:C24H34N8O2SColor and Shape:SolidMolecular weight:498.64AG-13958 monohydrochloride
CAS:AG-13958 monohydrochloride, a VEGFA inhibitor, may treat neovascular AMD to prevent rapid vision loss.Formula:C26H23ClFN7OColor and Shape:SolidMolecular weight:503.96c-ABL-IN-4
CAS:c-ABL-IN-4 is a potent inhibitor of c-Abl.Formula:C18H11ClF3N3O3Color and Shape:SolidMolecular weight:409.75c-ABL-IN-3
CAS:c-ABL-IN-3, from patent WO2021048567A1, is a potent c-Abl inhibitor for researching ALS, PD, and cancer.Formula:C17H11F3N4O3Color and Shape:SolidMolecular weight:376.29JAK-IN-20
CAS:JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.Formula:C28H30FN7O2Color and Shape:SolidMolecular weight:515.58Peficitinib hydrochloride
CAS:Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).Formula:C18H23ClN4O2Color and Shape:SolidMolecular weight:362.86BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Formula:C25H23N5O3Purity:98%Color and Shape:SolidMolecular weight:441.48J-1048
CAS:J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/Formula:C23H17FN6S2Color and Shape:SolidMolecular weight:460.55UNC-CA359
CAS:UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.Formula:C18H14ClN3O2Color and Shape:SolidMolecular weight:339.78NSC 33994
CAS:NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.Formula:C28H42N2O2Purity:98%Color and Shape:SolidMolecular weight:438.65JAK3/BTK-IN-6
CAS:JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2EGFR-IN-21
CAS:EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68BCR-ABL-IN-6
CAS:BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49VS 8
CAS:VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.Formula:C26H20F3N3O3Color and Shape:SolidMolecular weight:479.45EGFR/HER2-IN-2
CAS:EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11EGFR-IN-25
CAS:EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76EGFR-IN-54
CAS:EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51NSC114792
CAS:NSC114792 is a selective JAK3 inhibitor.Formula:C26H32N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.62EGFR-IN-52
CAS:EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.Formula:C19H18N4O3SColor and Shape:SolidMolecular weight:382.44EGFR/HER2/CDK9-IN-3
CAS:EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.Formula:C24H21N3O4S2Color and Shape:SolidMolecular weight:479.57SUN13837
CAS:SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.Formula:C21H29N5O2Color and Shape:SolidMolecular weight:383.49TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42EGFR/HER2-IN-3
CAS:EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49FLT3-IN-18
CAS:FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purity:99.05%Color and Shape:SolidMolecular weight:297.35Ref: TM-T72653
1mg145.00€5mg250.00€10mg340.00€25mg573.00€50mg879.00€100mg1,314.00€1mL*10mM (DMSO)462.00€EGFR-IN-69
CAS:EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64Flonoltinib
CAS:Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.Formula:C25H34FN7OPurity:99.52%Color and Shape:SolidMolecular weight:467.58VEGFR2 Kinase Inhibitor II
CAS:VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.Formula:C17H15BrN2OColor and Shape:SolidMolecular weight:343.22BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53CPL304110
CAS:CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54EGFR-IN-31
CAS:EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67FLT3/D835Y-IN-1
CAS:FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43EGFR-IN-57
CAS:EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.Formula:C22H15N3O2SColor and Shape:SolidMolecular weight:385.44EGFR-IN-60
CAS:EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.Formula:C28H28Cl2N6OColor and Shape:SolidMolecular weight:535.47ProMMP-9 inhibitor-3c
CAS:ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.Formula:C18H20FN3O2SColor and Shape:SolidMolecular weight:361.43ZT55
CAS:ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.Formula:C17H16N2O3Color and Shape:SolidMolecular weight:296.32VEGFR-2-IN-24
CAS:VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.Formula:C28H23N3O6SColor and Shape:SolidMolecular weight:529.56FGFR4-IN-11
CAS:FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.Formula:C29H29N5O5Color and Shape:SolidMolecular weight:527.57c-Met-IN-14
CAS:c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.Formula:C34H38ClFN4O7SColor and Shape:SolidMolecular weight:701.2BI-1622
CAS:BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53EGFR-IN-26
CAS:EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.Formula:C29H34N6O3Color and Shape:SolidMolecular weight:514.62TRK/ALK-IN-1
TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.Formula:C31H35ClF2N8O2SColor and Shape:SolidMolecular weight:657.18FGFR3-IN-1
CAS:FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).Formula:C28H39N9O3SColor and Shape:SolidMolecular weight:581.73PHM16
CAS:PHM16 is an ATP competitive FAK and FGFR2 inhibitor.Formula:C20H22N6O4Purity:98%Color and Shape:SolidMolecular weight:410.43EGFR-IN-49
CAS:EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.Formula:C13H11N3O2Color and Shape:SolidMolecular weight:241.25Erbstatin
CAS:Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.Formula:C9H9NO3Color and Shape:SolidMolecular weight:179.17PD-173956
CAS:PD-173956 is an inhibitor of the Src family tyrosine kinases.Formula:C20H13Cl2FN4OColor and Shape:SolidMolecular weight:415.25EGFR-IN-55
CAS:"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36Ficonalkib
CAS:Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.Formula:C29H39N7O3SColor and Shape:SolidMolecular weight:565.73EGFR/CDK2-IN-1
CAS:EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application inFormula:C19H12BrClO2Color and Shape:SolidMolecular weight:387.65Nazartinib mesylate
CAS:Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12MDK5466
CAS:MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.Formula:C21H23N3OSPurity:98%Color and Shape:SolidMolecular weight:365.49HIV-IN-6
CAS:HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.Formula:C20H16N4O3SPurity:97.78%Color and Shape:SolidMolecular weight:392.43Lavendustin C6
CAS:Lavendustin C6 is a effective tyrosine kinase inhibitor.Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formula:C29H31F3N8OPurity:98%Color and Shape:SolidMolecular weight:564.6BTK-IN-23
CAS:BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Formula:C27H28N6O2Color and Shape:SolidMolecular weight:468.55SMU-B
CAS:SMU-B is a well-tolerated c-Met/ALK dual inhibitor.Formula:C26H25Cl2FN4O2Purity:98%Color and Shape:SolidMolecular weight:515.41EGFR-IN-88
CAS:EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosisFormula:C22H18Cl2N4O2SPurity:98%Color and Shape:SolidMolecular weight:473.37BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49FGFR4-IN-5
CAS:FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Formula:C23H23Cl2N5O5Color and Shape:SolidMolecular weight:520.37DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97PDGFRα/FLT3-ITD-IN-1
CAS:PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.Formula:C27H39N9OColor and Shape:SolidMolecular weight:505.66Ebselen oxide
CAS:Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.Formula:C13H9NO2SePurity:98%Color and Shape:SolidMolecular weight:290.18KRC-108
CAS:KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.Formula:C20H20N6OColor and Shape:SolidMolecular weight:360.41EGFR/HER2-IN-9
CAS:EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFRFormula:C25H25ClFN5O4Color and Shape:SolidMolecular weight:513.95
